Manufacturers and their communications agencies see great opportunities in a new draft guidance from FDA, but the fear of warning letters still shadows the industry.
Market pressures have continued to threaten pharmaceutical brand revenue while increasing costs. The convergence of these two forces has challenged pharmaceutical manufacturers to improve margin with new and ever-evolving strategies. Only a combination of sophisticated managed markets expertise and real-world analysis can empower brands to maximize profitability in today’s challenging climate.
2017 Annual Report: State Of The Bio IndustryACA, Approvals, Biologics, Biosimilars, Biotech/Biopharma, Blockbusters, Business, Clinical Trials, Deals, FDA/Regulatory, June 2017, M&A, New Molecular Entities, Potential Blockbusters, Product Pipelines, R&D, Special Reports, State of the Bio Industry, Tufts Center for the Study of Drug Development
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
This chart shows the 2016 and 2015 revenue and R&D figures for some of the world’s leading biotech and biopharma companies.
Television as a marketing medium seems so, well, 1950s these days. Given the ubiquity of digital and mobile devices and the tracking and targeting opportunities they present, not to mention the lesser cost attached, blasting TV spots out to whomever might be watching could strike the uninformed as old-fashioned. But pharma’s top brand managers clearly don’t think so.
Med Ad News asked industry experts what they thought DTC communications might look like in five years. This is what they told us.
A listing of the top prescription brands by 2016 DTC spend according to Nielsen data.
A listing of the top prescription brands by DTC spend in 2016 according to Kantar Media data.
A listing of the top companies by total DTC spend in 2016 according to Nielsen data.
A listing of the top brands by DTC television spend in 2016 according to iSpot.tv data.